Alkermes plc has expanded its senior management team with the addition of two newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as senior vice president of Clinical Development and Medical Affairs, and Peter Norman has been named vice president of Government Affairs and Policy.
Dr. Stankovic will be responsible for advancing and implementing the clinical development programs for the company’s pipeline of drug candidates. He reports to Elliot Ehrich, M.D., senior vice president of R&D and chief medical officer. Dr. Stankovic has more than 20 years of R&D experience and has led multidisciplinary development teams for small molecules and biologics in numerous therapeutic areas. Most recently, he served as senior vice president and head of Global Clinical Development for Teva Pharmaceuticals.
Mr. Norman will lead activities at federal and state levels, as well as interactions with professional and patient organizations. He will report to Kathryn Biberstein, senior vice president, chief legal officer and chief compliance officer. Mr. Norman has significant experience in legislative and regulatory efforts as well as interactions with patient groups and healthcare coalitions. He has worked on public policy strategies related to a range of pharmaceutical products, as well as Medicare and Medicaid reimbursement, healthcare reform, DEA-controlled substance scheduling and biosimilars legislation. Most recently, he was head of the Washington, D.C. office of Eisai, Inc., where he directed government affairs and policy.
“We are very pleased to welcome Serge and Pete, two proven leaders whose expertise will contribute to Alkermes’ next stage of growth,” said Richard Pops, chief executive officer of Alkermes. “As our portfolio of new medicines expands, we are responding by strengthening our capabilities in two areas critical for our future: global clinical development and government affairs.”
Alkermes Expands Senior Management Team
Published September 30, 2013
blog comments powered by Disqus